Treating severe allergic asthma (SAA) with anti-IgE therapy (omalizumab) has a proven efficacy but is limited due to the dosing table of this medication, to a specific range of body weight and baseline blood total IgE levels (maximum level of total IgE of 1500 IU/mL in Europe). The gene discussed is IGHE; the disease is allergic asthma.